Studies from CSIR - Central Drug Research Institute Yield New Data on Antineoplastics (Simultaneous Estimation of Paclitaxel and Bortezomib Via Lc-ms/ms: Pharmaceutical and Pharmacokinetic Applications).

A recent study conducted in Uttar Pradesh, India, evaluated the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. The researchers optimized a nanoformulation using Box-Behnken Design and validated the method according to US-FDA guidelines. The size of the nanoformulation was found to be 133.9 +/- 1.97 nm, with promising pharmacokinetic results showing higher C-max for PTX-BTZ-NE compared to free PTX-BTZ. The study suggests that these findings could contribute to the treatment of breast cancer using PTX and BTZ. [Extracted from the article]